Peginterferon Alfa-2b And Ribavirin
Recommended · restricted HepatologyRestrictedFirst-line line
Treatment of chronic hepatitis C in patients with no or mild hepatitis C fibrosis, with removal of the liver biopsy requirement for eligibility determination.
1
Submissions
2005–05
On the record
$15k–45k
ICER range
1 sourced ICER · 2005
ICER stated
Cost basis
Access path
- Nov 2005Recommended · restricted
vs Pegatron therapy in patients with stage F1/A2-A3, F2, F3…
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
The PBAC accepted the conclusions from the modelled evaluation that treating hepatitis C patients earlier would be associated with an increase in both costs and outcomes per patient and that the incremental cost per extra QALY gained was acceptable and robust to important sources of uncertainty examined in the sensitivity analyses. PBAC · 2005
Decision context
PopulationPatients aged 18 years or older with chronic hepatitis C who have received no prior interferon therapy and have compensated liver disease with no or mild fibrosis (stages F0-F1/A0-A1).
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2005 | Recommended · restricted | Pegatron therapy in patients with stage F1/A2-A3, F2, F3 and F4 fibrosis | $15k–45k | RCT · SVR |